{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T21:26:22Z","timestamp":1788989182579,"version":"build-2803163510"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Gastroenterol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic dysfunction-associated steatohepatitis (MASH), formerly nonalcoholic steatohepatitis (NASH), is a progressive liver disease and a leading cause of cirrhosis and liver-related mortality worldwide, affecting approximately 3%\u20135% of the global adult population and up to 30%\u201340% of individuals with type 2 diabetes mellitus (T2DM) or those attending dedicated diabetes and endocrine centers. For decades, treatment was limited to lifestyle interventions. The years 2024 and 2025 marked a paradigm shift with the first-ever FDA approvals of pharmacologic agents for MASH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Scope<\/jats:title>\n                    <jats:p>This comprehensive narrative review synthesizes the evidence for newly approved and emerging pharmacotherapies for MASH, addressing the mechanisms of action, pivotal clinical trial data, efficacy, safety profiles, and place in therapy for resmetirom and semaglutide. It also discusses key agents including pioglitazone, saroglitazar, and vitamin E, and evaluates the non-invasive testing (NIT) toolkit\u2014including FIB-4, VCTE, shear wave elastography, MRE, and ELF\u2014in the context of a structured, risk-stratified clinical algorithm.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>Resmetirom (Rezdiffra), a THR-\u03b2 agonist, achieved MASH resolution in 26%\u201330% versus 10% placebo and fibrosis improvement in 24%\u201326% versus 14% placebo at 52 weeks in the MAESTRO-NASH trial. Semaglutide 2.4 mg (Wegovy) demonstrated a 28.7% delta over placebo in MASH resolution in the ESSENCE trial. Pioglitazone has additional evidence for reducing the FIB-4 index in real-world studies. Saroglitazar, a PPAR-\u03b1\/\u03b3 dual agonist approved in India, has shown significant reductions in ALT, liver fat, and metabolic parameters in Phase 2 studies and is advancing to Phase 2b. Shear wave elastography is a clinically important alternative to VCTE for fibrosis staging, particularly in patients with obesity, and offers value in resolving discordant FIB-4\/VCTE results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The approval of resmetirom and semaglutide marks a new era in MASH management. A risk-stratified algorithmic approach using NITs guides patient selection, with liver biopsy reserved for specific clinical scenarios. The therapeutic landscape is rapidly evolving, with saroglitazar and combination approaches representing key frontiers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fgstr.2026.1850915","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T04:33:02Z","timestamp":1784781182000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["The new era of MASH pharmacotherapy: a comprehensive review of FDA-approved and emerging agents"],"prefix":"10.3389","volume":"5","author":[{"given":"Abeer","family":"Qasim","sequence":"first","affiliation":[{"name":"Internal Medicine Department, BronxCare Health System","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayan","family":"Alataa","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, BronxCare Health System","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fnu","family":"Veena","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, BronxCare Health System","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elona","family":"Shehi","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, BronxCare Health System","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"B1","article-title":"Metabolic dysfunction-associated steatotic liver disease\u2014the worldwide burden","volume":"8","author":"Younossi","year":"2025","journal-title":"JAMA Netw Open"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000491","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"8","author":"Lazarus","year":"2024","journal-title":"Hepatol Commun"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multi-society Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001608","article-title":"Semaglutide therapy for metabolic dysfunctionassociated steatohepatitis: November 2025 updates to AASLD practice guidance","author":"Bansal","year":"2025","journal-title":"Hepatology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-025-01748-1","article-title":"Prevalence of metabolic dysfunction-associated steatotic liver disease: mapping across different Indian populations (MAP study)","volume":"16","author":"Jhaveri","year":"2025","journal-title":"Diabetes Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.lansea.2026.100753","article-title":"MASLD: time to optimise regional research priorities [editorial","year":"2026","journal-title":"Lancet Reg Health Southeast Asia"},{"key":"B7","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1053\/j.gastro.2015.06.012","article-title":"Liver fibrosis, the major determinant of long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v9.i11.533","article-title":"Hepatocellular carcinoma in non-alcoholic steatohepatitis: current knowledge and implications for management","volume":"9","author":"Cholankeril","year":"2017","journal-title":"World J Hepatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.cgh.2021.05.002","article-title":"Incidence of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression","volume":"20","author":"Orci","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.124.010912","article-title":"Risk of major adverse cardiovascular outcomes in metabolic dysfunctionassociated steatotic liver disease","volume":"17","author":"Ebrahimi","year":"2024","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.16367","article-title":"Projected trends in MASLD mortality through 2040","volume":"8","author":"Zhang","year":"2025","journal-title":"JAMA Netw Open"},{"key":"B13","unstructured":"FDA approves first treatment for patients with liver scarring due to fatty liver disease\n          \n          \n          \n          2024"},{"key":"B14","unstructured":"FDA approves treatment for serious liver disease known as MASH\n          \n          \n          \n          2025"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-083735","article-title":"Effect of dapagliflozin on metabolic dysfunction-associated steatotic liver disease: systematic review and meta-analysis of randomised controlled trials","volume":"389","author":"Lin","year":"2025","journal-title":"BMJ"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"B18","unstructured":"Prescribing information for Wegovy (semaglutide) injection"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s13410-025-01611-w","article-title":"Improving stratification of advanced fibrosis in metabolic dysfunction-associated steatotic liver disease patients with type-2 diabetes mellitus in low-resource settings","author":"Poh","year":"2026","journal-title":"Int J Diabetes Dev Ctries"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.70144","article-title":"Effectiveness of saroglitazar in MASLD patients: a prospective, realworld assessment of liver and metabolic health","volume":"9","author":"Gupta","year":"2026","journal-title":"Endocrinol Diabetes Metab"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.3390\/diagnostics15131598","article-title":"Comparing FIB-4, VCTE, pSWE, 2D-SWE, and MRE thresholds and diagnostic accuracies for detecting hepatic fibrosis in patients with MASLD: a systematic review and meta-analysis","volume":"15","author":"Wilson","year":"2025","journal-title":"Diagnostics"},{"key":"B22","article-title":"The structure of the thyroid hormone receptor-beta gene","volume":"6","author":"Kelly","year":"1992","journal-title":"Mol Endocrinol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001112","article-title":"Resmetirom therapy for metabolic dysfunctionassociated steatotic liver disease: October 2024 updates to AASLD practice guidance","volume":"81","author":"Chen","year":"2025","journal-title":"Hepatology"},{"key":"B25","article-title":"Prescribing information","year":"2024"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32689","article-title":"AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury","volume":"77","author":"Fontana","year":"2023","journal-title":"Hepatology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2024.10.054","article-title":"EUS-guided shear wave elastography for fibrosis screening in patients with obesity and MASLD: a pilot study","author":"Wang","year":"2024","journal-title":"Gastrointest Endosc"},{"key":"B32","article-title":"Breakthrough in treatment of MASLD\/NASH: Saroglitazar phase 2b (NCT05011300) update","year":"2024","journal-title":"ScienceDirect Rev"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1177\/30502071241281419","article-title":"Effects of SGLT2i and pioglitazone on FIB-4 index in patients with metabolic dysfunction associated steatotic liver disease\u2014a real world retrospective study from India","author":"Seshadri","year":"2025","journal-title":"Ther Adv Endocrinol Metab"},{"key":"B35","doi-asserted-by":"publisher","first-page":"37","DOI":"10.7326\/0003-4819-142-1-200501040-00110","article-title":"Meta-analysis: high-dosage vitamin E supplementation may increase allcause mortality","volume":"142","author":"Miller","year":"2005","journal-title":"Ann Intern Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"}],"container-title":["Frontiers in Gastroenterology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgstr.2026.1850915\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T04:33:11Z","timestamp":1784781191000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgstr.2026.1850915\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":36,"alternative-id":["10.3389\/fgstr.2026.1850915"],"URL":"https:\/\/doi.org\/10.3389\/fgstr.2026.1850915","relation":{},"ISSN":["2813-1169"],"issn-type":[{"value":"2813-1169","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"article-number":"1850915"}}